Let's make poor reporting of early phase dose finding clinical trials a thing of the past

被引：0
|
作者：
Yap, Christina [1 ]
机构：
[1] Inst Canc Res, Clin Trials & Stat Unit, London, England
来源：
BMJ-BRITISH MEDICAL JOURNAL | 2023年 / 383卷
关键词：
D O I：
10.1136/bmj.p2865
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Bayesian optimization design for finding a maximum tolerated dose combination in phase I clinical trials
    Takahashi, Ami
    Suzuki, Taiji
    INTERNATIONAL JOURNAL OF BIOSTATISTICS, 2022, 18 (01): : 39 - 56
  • [42] A Bayesian dose-finding design for phase I/II clinical trials with nonignorable dropouts
    Guo, Beibei
    Yuan, Ying
    STATISTICS IN MEDICINE, 2015, 34 (10) : 1721 - 1732
  • [43] A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation
    Abbas, Rachid
    Rossoni, Caroline
    Jaki, Thomas
    Paoletti, Xavier
    Mozgunov, Pavel
    CLINICAL TRIALS, 2020, 17 (05) : 522 - 534
  • [44] A dose-finding design for phase I clinical trials based on Bayesian stochastic approximation
    Jin Xu
    Dapeng Zhang
    Rongji Mu
    BMC Medical Research Methodology, 22
  • [45] Novel Statistical Designs for Phase I/II and Phase II Clinical Trials With Dose-Finding Objectives
    Oleksandr Sverdlov
    Weng Kee Wong
    Therapeutic Innovation & Regulatory Science, 2014, 48 : 601 - 612
  • [46] Novel Statistical Designs for Phase I/II and Phase II Clinical Trials With Dose-Finding Objectives
    Sverdlov, Oleksandr
    Wong, Weng Kee
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2014, 48 (05) : 601 - 612
  • [47] Pharmacokinetically guided optimum adaptive dose selection in early phase clinical trials
    Alam, M. Iftakhar
    Bogacka, Barbara
    Coad, D. Stephen
    COMPUTATIONAL STATISTICS & DATA ANALYSIS, 2017, 111 : 183 - 202
  • [48] SPIRIT-DEFINE explanation and elaboration: recommendations for enhancing quality and impact of early phase dose-finding clinical trials protocols
    Ursino, Moreno
    Villacampa, Guillermo
    Rekowski, Jan
    Dimairo, Munyaradzi
    Solovyeva, Olga
    Ashby, Deborah
    Berlin, Jordan
    Boix, Oliver
    Calvert, Melanie
    Chan, An-Wen
    Coschi, Courtney H.
    Evans, Thomas R. Jeffry
    Garrett-Mayer, Elizabeth
    Golub, Robert M.
    Guo, Christina
    Hayward, Kathryn S.
    Hopewell, Sally
    Isaacs, John D.
    Ivy, S. Percy
    Jaki, Thomas
    Kholmanskikh, Olga
    Kightley, Andrew
    Lee, Shing
    Liu, Rong
    Mander, Adrian
    Marshall, Lynley, V
    Matcham, James
    Patel, Dhrusti
    Peck, Richard
    Rantell, Khadija Rerhou
    Richards, Dawn P.
    Rouhifard, Mahtab
    Seymour, Lesley
    Tanaka, Yoshiya
    Weir, Christopher J.
    de Bono, Johann
    Yap, Christina
    ECLINICALMEDICINE, 2025, 79
  • [49] Practical model-based dose finding in early-phase clinical trials - Optimizing tissue plasminogen activator dose for treatment of ischemic stroke in children
    Whelan, Harry T.
    Cook, John D.
    Amlie-Lefond, Catherine M.
    Hovinga, Collin A.
    Chan, Anthony K.
    Ichord, Rebecca N.
    deVeber, Gabrielle A.
    Thall, Peter F.
    STROKE, 2008, 39 (09) : 2627 - 2636
  • [50] A clinical phase I dose-finding design with adaptive shrinking boundaries for drug combination trials
    Li, Zhaohang
    Xu, Ze
    Zhang, Aijun
    Qi, Guanpeng
    Li, Zuojing
    BMC MEDICAL RESEARCH METHODOLOGY, 2023, 23 (01)
12345